Endo Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio
Endo Pharmaceuticals (Malvern, PA): 30 reconciled FDA prescription therapies (8.7% 2025 to 2030 cliff risk), $253.8M 2024 CMS Part D & Medicaid spend, and 78 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Malvern, PA |
| Reconciled FDA Portfolio Therapies | 30 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 8.7% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $253.8M |
| 2024 Medicare Part D Spend | $190.6M |
| 2024 Medicaid Spend | $63.2M |
| California HCAI SB 17 Filings | 78 WAC filings (max 39.4% 2-yr change) |